Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

13.74 -0.12 (-0.87%)

Delayed Quote Updated: 11:34 AM EST, Nov 4, 2026 Add to My Watchlist

Price and Volume

Volume	354,777
Open	14.35
Bid (Size)	13.71 (500)
Ask (Size)	13.75 (100)
Prev. Close	13.86
Today's Range	13.48 - 14.53
52wk Range	9.820 - 20.22
Shares Outstanding	60,069,512
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Trevi Therapeutics Q2 Earnings Call Highlights ↗

August 07, 2026

Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio,...

Via MarketBeat

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗

June 03, 2026

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

Via The Motley Fool

Performance

52-Week Range 32.0% below 52-week high

13.74

9.8252W Low 20.2252W High

1 Week 3.4% below 1-week high

13.211W Low 14.231W High

Trevi Therapeutics, Inc. - Common Stock (TRVI) traded between $9.82 and $20.22 over the past 52 weeks and last traded at $13.74, 32.0% below its 52-week high. Over the past week it ranged between $13.21 and $14.23.

Past 12 Months

+1.6%

+0.1%

-26.7%

-6.3%

+15.6%

+28.4%

1W +$0.22

1M +$0.02

3M -$5.01

6M -$0.92

YTD +$1.85

1Y +$3.04

TRVI was +28.4% over the past year, -6.3% over six months, +15.6% year to date, +1.6% in the last week.

12 Months vs Market

TRVI

+28.4%

DIA

+12.5%

SPY

+12.4%

QQQ

+9.6%

IWM

+15.6%

Over the past 12 months TRVI returned +28.4% versus DIA (Dow) +12.5%, SPY (S&P 500) +12.4%, QQQ (Nasdaq 100) +9.6% and IWM (Russell 2000) +15.6%.

Volume & Liquidity 0.18× 3-mo avg

Today 354,777 3-mo avg 1.9M

1.4M

2.5M

1.9M

2.0M

YTD

1.8M

TRVI most recently traded 354,777 shares against a 3-month average daily volume of 1.9M.

More News

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 ↗

May 09, 2026

Via MarketBeat

Trevi Therapeutics Inc. (NASDAQ:TRVI) Beats Q4 2025 EPS Estimates, Gains FDA Alignment for Phase 3 Program ↗

March 17, 2026

Via Chartmill

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Preview For Trevi Therapeutics ↗

May 07, 2025

Via Benzinga

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗

March 23, 2026

Via The Motley Fool

Trevi Therapeutics (TRVI) Earnings Transcript ↗

March 18, 2026

Via The Motley Fool

TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns ↗

March 09, 2026

Via Stocktwits

MarketBeat’s Top 5 Rated Small-Cap Stocks ↗

December 22, 2025

Via MarketBeat

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

Via The Motley Fool

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

Via The Motley Fool

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Via The Motley Fool

Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans ↗

November 13, 2025

Via Chartmill

A Peek at Trevi Therapeutics's Future Earnings ↗

November 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 03, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

August 21, 2025

Via Benzinga

Dow Gains Over 100 Points; US Job Openings Increase In April ↗

June 03, 2025

Via Benzinga

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients ↗

June 02, 2025

Via Benzinga

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

March 26, 2025

From Avalo Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Trevi Therapeutics, Inc. - Common Stock publicly traded?

Yes, Trevi Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Trevi Therapeutics, Inc. - Common Stock trade on?

Trevi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Trevi Therapeutics, Inc. - Common Stock?

The ticker symbol for Trevi Therapeutics, Inc. - Common Stock is TRVI on the Nasdaq Stock Market

What is the current price of Trevi Therapeutics, Inc. - Common Stock?

The current price of Trevi Therapeutics, Inc. - Common Stock is 13.74

When was Trevi Therapeutics, Inc. - Common Stock last traded?

The last trade of Trevi Therapeutics, Inc. - Common Stock was at 11/04/26 11:34 AM ET

What is the market capitalization of Trevi Therapeutics, Inc. - Common Stock?

The market capitalization of Trevi Therapeutics, Inc. - Common Stock is 825.36M

How many shares of Trevi Therapeutics, Inc. - Common Stock are outstanding?

Trevi Therapeutics, Inc. - Common Stock has 825M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.